The deal is a dramatic bet that the London-based drug giant can see opportunities connected to the genetics of cancer drugs better than the stock market. It fits into a framework outlined in July by Hal Barron, the widely respected pharma veteran who took over as GSK’s head of R&D last year.
GSK Buys Tesaro For $5 Billion In Dramatic Bet On Cancer Genetics
